← Back

iRay Technology Co Ltd

iRay Group, together with its subsidiaries, researches, develops, produces, sells, and services x-ray system components and micro-display backplanes for use in medical, dental, oncology, veterinary, security, and nondestructive testing applications in China and internationally. The company offers wireless and tethered radiography, mammography, and dynamic/real-time detectors; linear detector arrays; X-ray and micro focus X-ray sources; high voltage generators; radiation detecting materials; software; and other products. It is also involved in the technology and product development; customer service; and investment and management activities. The company exports its products to approximately 80 countries. The company was formerly known as iRay Technology Company Limited and changed its name to iRay Group in February 2025. iRay Group was incorporated in 2011 and is headquartered in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 688301.CG
688301.CG▼

Yirui Technology Releases 2026 Interim Report with Net Profit of 406 Million Yuan

Yirui Technology released its 2026 interim report, with net profit attributable to the parent company of 406 million yuan. The company's total operating revenue was 1.671 billion yuan, and net cash inflow from operating activities was 378 million yuan, a decrease of 53.75% compared with the same period last year. The latest asset-liability ratio was 38.66%, and the gross margin was 47.68%, a decrease of 5.29 percentage points from the same period last year. Return on equity was 5.24%, down 1.65 percentage points year on year. Diluted earnings per share were 1.37 yuan, total asset turnover was 0.13 times, and inventory turnover was 1.01 times. The number of shareholders was 20,000, and the top ten shareholders held 131 million shares, accounting for 42.07% of the total share capital.
688301.CG ▼
Jiemian·13dRead more ▾
688301.CG▲3

iRay Technology's net profit for the first half of 2026 grows 21.25% year on year

iRay Technology released its semi-annual report for 2026, achieving operating revenue of 1.671 billion yuan, up 56.66% year on year; net profit attributable to shareholders of the listed company was 406 million yuan, up 21.25% year on year. Second-quarter net profit was 227 million yuan, first-quarter net profit was 179 million yuan, and second-quarter net profit rose 26% quarter on quarter.
688301.CG ▲
CLS·13dRead more ▾
Biotech & Genomic Medicine▲

Globally Co-Developed Innovative Drug First Approved and Launched in China, STAR Market Healthcare ETF Huaxia Turns Positive in Afternoon

An innovative drug with a new target, co-developed and filed for approval globally, has been approved for market launch first in China, marking a historic breakthrough where an original-target innovative drug from global multi-center development is first reported and launched in China. The National Medical Products Administration has newly approved a selective orexin-2 receptor agonist for the treatment of type 1 narcolepsy in adolescents and adults aged 16 and above. Boosted by this news, the STAR Market Healthcare ETF Huaxia turned positive in the afternoon, rising 0.58 percent to 1.05 yuan, with intraday turnover of 11.46 percent and trading volume of 41.29 million yuan. The SSE STAR Market Biomedical Index rose 0.69 percent, with constituent stocks Medici rising 8.95 percent, Yirui Technology up 8.93 percent, and BeiGene gaining 6.29 percent.
688202.CG ▲688235.CG ▲688301.CG ▲
Biotech & Genomic Medicine ▲
Jiemian·37dRead more ▾
688301.CG▼

iRay Technology’s de facto controller Gu Tie embroiled in share reduction and related-party transaction controversy

The employee stock ownership platform controlled by iRay Technology’s de facto controller Gu Tie has once again disclosed a share reduction plan, drawing market attention to corporate governance and related-party transactions. Since 2025, three employee stock ownership platforms have reduced their holdings by over 7 million shares, cashing out a total of nearly 700 million yuan. This coincides with another company controlled by Gu Tie, SeeYA Technology, sprinting toward a listing on the STAR Market. Meanwhile, the scale of related-party transactions between iRay Technology and SeeYA Technology has been significantly raised, with the projected transaction amount for 2026 increasing from 120 million yuan to 860 million yuan, accounting for 38.53% of the estimated similar business, and adopting a tripartite transaction model designated by downstream customers. Gu Tie concurrently serves as chairman, general manager, and core technical personnel of iRay Technology, and his governance structure of controlling multiple industrial platforms faces a test of independence. In addition, early investor Sequoia Capital has been continuously reducing its holdings since 2022, with its shareholding ratio dropping sharply from 14.75%.
688301.CG ▼
财中社·38dRead more ▾
688301.CG▲

Medical device sector reaches inflection point, STAR Healthcare ETF ChinaAMC holds over 34% in devices

A research note from China Securities points out that the medical device sector has reached an inflection point. In the first quarter of 2026, the pharmaceutical industry's total revenue grew 2.16% year on year, while core net profit attributable to shareholders rose 2.69%, showing an improving trend. The STAR Biomedical Index tracked by the STAR Healthcare ETF ChinaAMC has a medical device weighting exceeding 34%, with the top ten holdings including device leaders such as United Imaging Healthcare, Yirui Technology, and Huitai Medical. China Securities believes that as the impact of policies like volume-based procurement gradually fades, the device sector is poised for a dual recovery in valuations and earnings, with key opportunities coming from earnings recovery, overseas expansion, surgical robots, and brain-computer interfaces. As of 10 July 2026, the latest circulating size of the STAR Healthcare ETF ChinaAMC reached 249 million yuan, a new high over the past year.
688271.CG ▲688301.CG ▲688617.CG ▲
Choice·45dRead more ▾
© 2026 MarketDXAsset